Profound Medical (PROF)
(Delayed Data from NSDQ)
$9.87 USD
-0.73 (-6.89%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.84 -0.03 (-0.30%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PROF 9.87 -0.73(-6.89%)
Will PROF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PROF
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
Other News for PROF
Profound Medical (PRN) Receives a Buy from Lake Street
Profound Medical initiated with bullish view at Lake Street, here's why
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 ? Conference Call to Follow
Profound Medical Unveils Q2 2024 Financials
Profound Medical upgraded at Stifel on Medicare policy update